[Clinical evaluation of imipenem/cilastatin sodium in the pediatric field].
Imipenem/cilastatin sodium (MK-0787/MK-0791) was evaluated for its safety and efficacy in 7 pediatric patients with infections. The clinical efficacy ratio was 100 percent. No side effect was observed except for elevations of S-GOT and S-GPT and eosinophilia in 1 patient. It may be considered that MK-0787/MK-0791 is a safe and useful antibiotic for the treatment of pediatric infections.
Hirosawa
H
H
Hoshina
H
H
Morikawa
Y
Y
Ichihashi
H
H
D001424:Bacterial Infections / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D015377:Cilastatin; D003521:Cyclopropanes / Q000008:administration & dosage* / Q000378:metabolism; D004338:Drug Combinations; D005260:Female; D006801:Humans; D015378:Imipenem; D007223:Infant; D007700:Kinetics; D008199:Lymphadenitis / Q000188:drug therapy; D008297:Male; D012141:Respiratory Tract Infections / Q000188:drug therapy; D013845:Thienamycins / Q000008:administration & dosage* / Q000378:metabolism; D014552:Urinary Tract Infections / Q000188:drug therapy
D003521:Cyclopropanes; D004338:Drug Combinations; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem